Iovance Therapeutics’ stock dropped more than 44% on Friday afternoon, a day after the company slashed its 2025 sales ...

Illumina on Thursday said the SEC has closed its investigation into the company's $8 billion purchase of Grail and doesn't ...

Patrik Jonsson becomes International president, Ilya Yuffa leads USA division, Kenneth Custer takes over Cardiometabolic ...

Endpoints platform launches new profile system with improved account management features, including streamlined newsletter ...

Revolution Medicines reports positive data for KRAS-targeting cancer drug elironrasib, showing higher response rates vs Amgen ...

AstraZeneca lost its challenge to Medicare drug price negotiations in the first appeals court ruling on the merits of the ...

Boston-based Verastem Oncology on Thursday won accelerated approval from the FDA for Avmapki Fakzynja as a second-line ...

The FDA is still reviewing a label expansion for GSK’s respiratory drug Nucala in chronic obstructive pulmonary disease ...

Vor Bio, founded by famed cancer biologist Siddhartha Mukherjee, is looking for a way out. Its decision to pursue strategic ...

After working off $20 million in seed funding for about four years, HAYA Therapeutics tapped the funding well and came back ...

Illumina estimates about $85 million in costs this year related to tariffs on its DNA sequencing products, the company said ...

Attorneys general from 19 states and Washington, DC have filed a lawsuit against the federal government alleging that its ...